The long term goal of this proposal is to develop strategies for the treatment of, and for the prevention of breast cancer. In earlier phases of our research, we developed selective aromatase inhibitors for blockade of estrogen synthesis as a treatment strategy. Recently, we have identified aromatase expression and mRNA in epithelial cells of both normal breast and breast cancers. In this application, we propose to investigate the significance of in situ estrogen production to tumor development and progression, mechanisms involved in aromatase regulation in the breast and the effect of aromatase inhibitors and antiestrogens on these processes. We propose studies to establish whether there is an association between in situ estrogen production and growth response in normal human breast and breast cancer tissues, as indicated by our preliminary studies. Measurement of proliferation ([3H]-thymidine incorporation) of breast tumors in histocultures in response to aromatase substrate (testosterone) will be carried out in the presence/absence of aromatase inhibitors, 4-OHA or CGS 20267. Also, immunostaining of tumor sections for proliferating nuclear antigen (PCNA) a marker of cell proliferation, aromatase and estrogen receptors will be used. Some studies suggest that in situ estrogen synthesis may be the major source of estrogen in the breast. We will measure the extent to which in situ estrogen synthesis contributes to total estrogen concentrations in the normal mammary gland in vivo using the baboon model. Epithelial, myoepithelial and stromal cells will be isolated from normal human breast tissue and from aromatase/proliferative positive tumors. The isolated cells will be characterized for a) aromatase activity b) aromatase expression c) aromatase mRNA. As indicators of their response to in situ estrogen production by androgen aromatization, we will measure a) induction of progesterone receptor d) tumor cell proliferation e) tumor cell invasiveness. We propose to identify promoter-regions of the aromatase gene involved in regulation of aromatase expression in isolated epithelial cells from normal breast and breast cancers. Factors will be determined which regulate aromatase expression in epithelial cells of normal breast and breast cancers. This will include a) stimulation by cAMP analogs, glucocorticoids, IL-6 and other cytokines; b) inhibition by estradiol, TGFbeta, inhibin/activin c) effects of stromal cell interaction in vitro. Finally, we will investigate whether in situ estrogen production by tumor epithelial cells is sufficient to promote their growth in vivo in the nude mouse model and whether the factors identified regulate aromatase expression in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA062483-17S2
Application #
6126515
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Mohla, Suresh
Project Start
1980-09-01
Project End
2000-03-31
Budget Start
1998-05-01
Budget End
2000-03-31
Support Year
17
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Schech, Amanda J; Shah, Preeti; Yu, Stephen et al. (2015) Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 152:499-508
Khatri, Raju; Shah, Preeti; Guha, Rupa et al. (2015) Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Mol Cancer Ther 14:1728-37
Sabnis, Gauri J; Kazi, Armina; Golubeva, Olga et al. (2013) Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat 138:699-708
Schech, Amanda J; Kazi, Armina A; Gilani, Rabia A et al. (2013) Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-?B. Mol Cancer Ther 12:1356-66
Sabnis, Gauri J; Goloubeva, Olga G; Kazi, Armina A et al. (2013) HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol Cancer Ther 12:2804-16
Gilani, Rabia A; Kazi, Armina A; Shah, Preeti et al. (2012) The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 135:681-92
Hursting, Stephen D; Digiovanni, John; Dannenberg, Andrew J et al. (2012) Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) 5:1260-72
Tobin, Lisa A; Robert, Carine; Nagaria, Pratik et al. (2012) Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res 10:96-107
Schech, Amanda J; Nemieboka, Brandon E; Brodie, Angela H (2012) Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction. J Steroid Biochem Mol Biol 132:195-202
Tilghman, Syreeta L; Sabnis, Gauri; Brodie, Angela M H (2011) Upregulation of AIB1, aromatase and ER* provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival. Horm Mol Biol Clin Investig 3:357-366

Showing the most recent 10 out of 56 publications